INTRODUCTION
============

Stroke is a major cause of neurological disability, resulting in various negative psychological consequences, including depression, fatigue, and anxiety. Extensive research has been conducted on post-stroke depression (PSD), and patients with PSD generally show higher morbidity and mortality rates than those without PSD \[[@b1-pi-2019-0188],[@b2-pi-2019-0188]\]. Post-stroke anxiety (PSA) is also a significant psychiatric symptom in stroke patients, affecting more than one-quarter of stroke survivors \[[@b3-pi-2019-0188]\]. However, in contrast to PSD, studies on PSA and its relationship to functional outcomes, including stroke severity, activities of daily living (ADLs), and cognitive function are relatively limited, and have drawn inconsistent conclusions.

An early study reported that stroke patients with generalized anxiety had no significant differences in social, cognitive, or physical functions, compared to the those without anxiety after more than 2 years of follow-up after stroke \[[@b4-pi-2019-0188]\]. However, in the same dataset, PSA was significantly related to the impairment of ADLs during the acute phase but not the chronic phase of stroke \[[@b5-pi-2019-0188]\]. Two studies reported no association between anxiety measured within 6 months after stroke and functional recovery 5--10 years later \[[@b6-pi-2019-0188],[@b7-pi-2019-0188]\]. However, positive findings have been reported in more recent studies. One study reported that anxiety during the acute phase of stroke was significantly associated with lower levels of ADLs 3 months after stroke \[[@b8-pi-2019-0188]\]. Another study reported that PSA significantly predicted poor functional outcomes even 10 years after stroke \[[@b9-pi-2019-0188]\]. However, these studies assessed functional outcomes only by the level of ADLs or used the modified Rankin scale.

Previous studies were limited in terms of heterogeneous evaluation points, not being comprehensive investigations on functional outcomes, and using just one anxiety estimate, all of which may have rendered inconsistent findings \[[@b4-pi-2019-0188]-[@b9-pi-2019-0188]\]. Therefore, the present study investigated the impact of PSA on three major categories of functional outcomes, cognitive function, physical ADLs, and neurological impairment, during the acute (2 weeks) and chronic phases (1 year) after the index stroke.

METHODS
=======

Study outline
-------------

This analysis is part of a larger parent study designed to investigate psychiatric disorders of stroke patients hospitalized in the Department of Neurology at Chonnam National University Hospital, Gwangju, South Korea. Participants were individually evaluated 2 weeks and 1 year post-stroke. Anxiety and functional outcomes were evaluated 2 weeks and 1 year after stroke. Demographic and clinical characteristics were collected at 2 weeks.

Participants
------------

Participants were consecutively recruited from all patients with recent ischemic stroke hospitalized within the Department of Neurology at Chonnam National University Hospital, Gwangju, South Korea between March 2006 and December 2009. The eligible participants were recruited about 2 weeks after the initial diagnosis of stroke. The inclusion criteria were: 1) patients with an ischemic stroke confirmed by a neuroimaging technique, such as brain magnetic resonance imaging (MRI) and computed tomography (CT), within 7 days; 2) patients that could adequately cooperate with staff and complete the questionnaires and assessments; and 3) patients capable of fully comprehending the objective of this study and providing informed consent. The exclusion criteria were: 1) patients with a severe physical illness that might lead to a life-threatening condition or patients whose course of recovery might be interrupted by this study; 2) patients with communication difficulties due to dysphagia or severe hearing impairment; 3) patients with any of the following comorbid neuropsychiatric conditions: dementia, Parkinson's disease, psychosis, substance abuse, brain tumor, or epilepsy; 4) patients with a pre-existing physical restriction prior to stroke; and 5) patients with a Mini Mental State Examination (MMSE) score \<16. This study strictly followed the code of ethics enforced by the Institutional Review Board of Chonnam National University Hospital (IRB No. I-2008-02-028), and all participants provided written informed consent.

Measurement and assessment of anxiety
-------------------------------------

The Hospital Anxiety and Depression Scale (HADS) \[[@b10-pi-2019-0188]\] was used to determine anxiety symptoms. The HADS was created to assess patients with a physical comorbidity using two 7-item subscales that evaluate depression and anxiety. Individual items are rated on a 4-point (0--3) scale. The total score (HADS-T; 0--42) reflects scores on two subscales: a score of 0--21 for the anxiety subscale (HADS-A) and a score of 0--21 for the depression subscale (HADS-D). HADS-A was employed to assess the levels of anxiety in the participants. The presence of PSA was defined as a HADS-A score ≥7, as described previously \[[@b7-pi-2019-0188],[@b11-pi-2019-0188],[@b12-pi-2019-0188]\]. HADS has been validated in stroke patients and the optimal cut-off has been presented as HADS-A score ≥7 \[[@b11-pi-2019-0188],[@b12-pi-2019-0188]\]. The HADS has been formally translated and standardized in Korean \[[@b13-pi-2019-0188]\]. Each individual participant completed the HADS-A 2 weeks and 1 year after their stroke to evaluate the acute and chronic states of anxiety, respectively.

Measurement and assessment of functional outcome post-stroke
------------------------------------------------------------

All participants were evaluated for functional outcomes in three categories: neurological severity, physical disability, and cognitive impairment.

### National Institutes of Health Stroke Scale (NIHSS)

The NIHSS \[[@b14-pi-2019-0188]\] is a systematic assessment tool that provides a quantitative measure of stroke-related neurological deficits. The NIHSS is composed of 11 items that measure motor and sensory functions, language and speech production, vision, level of consciousness, and attention and neglect. Each item assesses a specific functional ability based on a score from 0 to 4. For each item, a lower score indicates normal, whereas a higher score indicates a higher level of neurological severity.

### Barthel Index (BI)

The BI \[[@b15-pi-2019-0188]\] is an objective tool based on an ordinal scale to measure performance of ADLs. The BI is composed of 10 variables that indicate the following ADLs: mobility, feeding, toilet use, dressing, bathing, fecal and urinary incontinence, help with grooming, and other activities. A higher number is associated with a greater likelihood of achieving independence with ADLs after discharge. Each item is scored as 0, 5, or 10 points; therefore, BI scores can range from 0 to 100, corresponding to five levels of physical restrictions in ADLs: independence (100 points), low dependence (91--99 points), moderate dependence (61--90 points), severe dependence (21--60 points), and total dependence (0--20).

### Mini Mental Status Examination (MMSE)

The MMSE \[[@b16-pi-2019-0188]\] measures cognitive function and is composed of 30 questions. A score of 1 indicates a positive outcome whereas a score of 0 indicates a negative outcome for each item. The MMSE measures the following domains of functional abilities: registration, attention and calculation, recall, language, ability to follow simple commands, and orientation. Lower scores represent greater cognitive impairment.

Demographic and clinical characteristics
----------------------------------------

The following demographic and clinical characteristics associated with PSA7 \[[@b17-pi-2019-0188]-[@b19-pi-2019-0188]\], were recorded: age, gender, years of education, history of depression and stroke, stroke localization by hemisphere (left, right, or bilateral), and location (anterior, posterior, or both) according to neuroimaging, such as brain MRI or CT. Vascular risk or disease was evaluated as hypertension, diabetes, heart disease, and hypercholesterolemia. Body mass index and smoking status were recorded. Depression was assessed by a structured psychiatric interview according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria using the Mini International Neuropsychiatric Interview \[[@b20-pi-2019-0188]\] and depressive symptoms were assessed by the Hamilton Depression Rating Scale (HAMD) \[[@b21-pi-2019-0188]\].

Statistical analysis
--------------------

The dependent variables were PSA 2 weeks and 1 year after stroke. The demographic and clinical characteristics at baseline were compared by PSA status using the t-test or the chi-squared (*χ*^2^) test, as appropriate, at each evaluation point. All variables significantly associated (p\<0.05) with PSA at each point were considered covariates in later adjusted analyses. Cross-sectional associations between PSA and functional outcomes during the acute and chronic phases of stroke were analyzed using a t-test in the unadjusted model, and by logistic regression tests after adjusting for potential covariates. Finally, the longitudinal associations between acute phase PSA and changes in functional outcomes over 1 year were assessed using repeated-measures analysis of variance (ANOVA) in the same adjusted model. All statistical analyses were carried out using SPSS 23.0 software (IBM Corp., Armonk, NY, USA).

RESULTS
=======

Recruitment
-----------

The recruitment procedure of the present study is shown in [Figure 1](#f1-pi-2019-0188){ref-type="fig"}. Of the 465 consecutively enrolled stroke patients who met the inclusion and exclusion criteria, 423 (91%) consented to participate in the study. No significant differences in demographic or clinical characteristics were found between the participants and nonparticipants at this stage (all p\>0.1). A total of 306 of 423 participants (72.3%) successfully completed the follow-up assessment at 1 year. The baseline demographic and clinical characteristics were not significantly different between those who were and were not available for the follow up assessment (all p\>0.1).

Demographic and clinical characteristics by PSA
-----------------------------------------------

PSA was diagnosed in 27 (6.4%) of 423 and 30 (9.8%) of 306 participants 2 weeks and 1 year after the index stroke, respectively. The baseline demographic and clinical characteristics were compared by PSA status at each evaluation point in [Table 1](#t1-pi-2019-0188){ref-type="table"}. The presence of PSA at the acute phase was significantly associated with female gender, history of depression, and a higher HAMD score. The presence of PSA at the chronic phase was significantly associated with a higher HAMD score at baseline.

Cross-sectional associations between PSA and functional outcomes
----------------------------------------------------------------

Cross-sectional associations between PSA and functional outcomes during both the acute and chronic phases of stroke are summarized in [Table 2](#t2-pi-2019-0188){ref-type="table"}. PSA at the acute phase was significantly associated with a lower MMSE score at baseline in the unadjusted analysis. However, the strength of the association lost significance after adjusting for gender, history of depression, and the HAMD score. PSA during the chronic phase was significantly associated with a higher NIHSS score, and lower BI and MMSE scores at follow-up in both unadjusted and adjusted analyses using the same model.

Longitudinal associations between PSA at acute phase and changes in functional outcomes
---------------------------------------------------------------------------------------

The longitudinal associations between PSA during the acute phase and changes in the three functional outcomes over 1 year in the 306 participants who completed the follow-up evaluation are displayed in [Figure 2](#f2-pi-2019-0188){ref-type="fig"}. No significant group differences were observed for any of the three outcomes. However, there were significant group×time interactions for changes in the NIHSS and BI score after adjusting for gender, history of depression, and baseline HAMD score. The NIHSS and BI scores worsened over 1 year in the presence of PSA at baseline.

DISCUSSION
==========

The main findings of this longitudinal study in a stroke cohort were that PSA at the acute phase was not associated with functional outcomes at the cross-sectional point, but predicted a worsening of stroke severity outcome and ADLs 1 year after stroke. PSA during the chronic phase was cross-sectionally associated with poor functional outcome 1 year after stroke. All associations were independent of potential covariates.

PSA was not associated with the functional status of stroke at the baseline examination. This result was discordant with that from PSD, which has been reported to be significantly associated with poor functional status during the acute phase of stroke \[[@b5-pi-2019-0188],[@b22-pi-2019-0188]\]. However, it was consistent with previous studies on the associations between PSA and functional outcomes during the acute phase \[[@b8-pi-2019-0188]\]. Stroke is a life-threatening attack that results in severe stress to patients \[[@b23-pi-2019-0188]\]. Therefore, anxiety may develop due to the stroke itself rather than to stroke functional status. A novel finding of this study was that PSA during the acute phase predicted a worsening of long-term stroke severity and ADLs over the 1-year time span, i.e., patients with PSA during the acute phase showed a worsening trajectory in neurological severity and physical disability, whereas those without PSA showed a generally improved disease prognosis ([Figure 2](#f2-pi-2019-0188){ref-type="fig"}). Although the finding on cognitive function measured with the MMSE was not significant (group×time interaction p=0.099), it also showed a similar trend. Several explanations are plausible. First, treatment after a stroke becomes focused on improving general health and functional status. The presence of anxiety at this time can reduce social engagement, independence in ADLs, and health-related quality of life of survivors \[[@b8-pi-2019-0188],[@b24-pi-2019-0188],[@b25-pi-2019-0188]\]. Second, anxiety may lead to a pessimistic outcome of rehabilitation resulting in poor adherence to treatments \[[@b26-pi-2019-0188]\]. Third, comorbidity with depression should be considered, as PSD is a well-known predictor of poor stroke outcome \[[@b27-pi-2019-0188],[@b28-pi-2019-0188]\]. In this study, depressive symptoms measured by the HAMD at baseline were significantly associated with PSA during the acute and chronic phases of stroke, consistent with a previous study \[[@b29-pi-2019-0188]\]. However, the association between PSA during the acute phase and worsening of functional status remained significant after adjusting for depressive symptoms.

Additionally, PSA was associated with a poor functional outcome during the chronic phase of stroke. This is a cross-sectional finding that replicates previous studies with a similar design \[[@b5-pi-2019-0188],[@b7-pi-2019-0188],[@b8-pi-2019-0188]\]. However, this finding is particularly important when considering that PSA was not associated with any functional outcomes during the acute phase of stroke. Unlike the acute phase when patients are overwhelmed by a stroke, patients are more coherently aware of their functional status during the chronic phase; therefore, those with severe stroke are more vulnerable to anxiety. This finding suggests that PSA may be a state marker of functional outcome during the chronic but not the acute phase of stroke.

Before drawing a conclusion, several issues should be considered. First, the prevalence of PSA in this study was lower (6.4% at 2 weeks and 9.8% at 1 year after stroke) compared to that in other studies, such as approximately 25% in meta-analyses \[[@b29-pi-2019-0188],[@b30-pi-2019-0188]\]. This can be explained by the strict recruitment criteria of the present study, as patients with severe cognitive impairment or aphasia who could not complete the self-rating scales or psychiatric interview were excluded from the study; thus, the generalizability of our results is limited to people with mild to moderate stroke severity without these deficits. Second, although the HADS is a well-validated and simple approach that has been used in previous studies on stroke, our study has limitation of using only a self-reported questionnaire HADS to assess PSA, not using a structured diagnostic interview. According to recent study, subtypes of anxiety disorder in stroke patients are important and phobic predominant patients are associated with poorer patient outcomes \[[@b31-pi-2019-0188]\]. Further research will also need to investigate the functional consequences of post stroke anxiety subtype based on structured diagnostic interview. Third, there was attrition in the recruitment process, although no difference was found between participants vs. nonparticipants in any of the characteristics evaluated at baseline.

The present study had several strengths. This study was the first to investigate the longitudinal associations between functional status and PSA by assessing the presence of anxiety and a range of covariates with well-validated assessment scales at similar time points (2 weeks and 1 year after stroke) in all participants. Because the etiology of anxiety may differ according to the time elapsed after stroke, the particular design used in the present study diminished the risk of errors due to different examination times. Additionally, the participants were consecutively recruited from among all eligible patients being treated for a recent stroke at the study hospital, which reduced the possibility of selection bias and increased potential generalizability.

In conclusion, screening for anxiety and depression is recommended even during the acute phase of stroke considering their independent detrimental effects on functional prognosis. Based on our findings, future studies should clarify the impact of acute phase PSA on long-term functional outcomes after stroke, such as the treatment effects of PSA using randomized controlled study designs and to establish the underlying mechanisms, including biological, behavioral, and social factors that contribute to this relationship, such as treatment adherence and trait negative response bias. In addition, screening for anxiety during the chronic phase is also encouraged, as this may reflect the functional status of stroke.
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###### 

Baseline characteristics according to anxiety 2 weeks and at 1 year after stroke

                                                Acute (2 weeks)   Chronic (12 months)                                        
  --------------------------------------------- ----------------- --------------------- --------- ------------ ------------- ---------
  Age, mean (SD) years                          64.6 (10.1)       62.4 (9.3)            0.237     63.6 (9.8)   64.3 (10.9)   0.746
  Gender, N (%) female                          159 (40.2)        20 (74.1)             0.001     109 (39.5)   17 (56.7)     0.069
  Education, mean (SD) year                     8.6 (4.9)         7.1 (4.6)             0.113     8.8 (4.9)    7.4 (5.2)     0.176
  Previous depression, N (%)                    13 (3.3)          4 (14.8)              0.003     9 (3.3)      3 (10.0)      0.071
  Previous stroke, N (%)                        31 (7.8)          4 (14.8)              0.202     20 (7.2)     5 (16.7)      0.074
  Stroke hemisphere, N (%)                                                                                                   
   Left                                         178 (44.9)        15 (55.6)             0.185     134 (48.6)   13 (43.3)     0.848
   Right                                        201 (50.8)        9 (33.3)                        132 (47.8)   16 (53.3)     
   Bilateral                                    17 (4.3)          3 (11.1)                        10 (3.6)     1 (3.3)       
  Stroke location, N (%)                                                                                                     
   Anterior                                     216 (54.5)        18 (66.7)             0.126     152 (55.1)   21 (70.0)     0.272
   Posterior                                    146 (36.9)        5 (18.5)                        103 (37.3)   8 (26.7)      
   Both                                         34 (8.6)          4 (14.8)                        21 (7.6)     1 (3.3)       
  Vascular risk/disease, N (%)                                                                                               
   Hypertension                                 194 (49.0)        13 (48.1)             0.933     134 (48.6)   17 (56.7)     0.398
   Diabetes                                     110 (27.8)        6 (22.2)              0.531     76 (27.5)    8 (26.7)      0.919
   Heart disease                                33 (8.3)          3 (11.1)              0.617     26 (9.4)     2 (6.7)       0.619
   Hypercholesterolemia                         221 (55.8)        15 (55.6)             0.980     164 (59.4)   15 (50.0)     0.320
  Body mass index, mean (SD) kg/m^2^            24.1 (2.8)        24.3 (2.9)            0.664     24.3 (2.8)   23.8 (3.0)    0.366
  Smoking, N (%) current smoker                 66 (16.7)         3 (11.1)              0.127     52 (18.8)    4 (13.3)      0.706
  Hamilton Depression Rating Scale at 2 weeks   6.5 (5.2)         18.0 (5.8)            \<0.001   6.6 (5.3)    11.6 (6.7)    \<0.001

p-value using t-tests, χ^2^ tests, or Fisher's exact tests as appropriate.

PSA: Post-Stroke Anxiety

###### 

Cross-sectional associations between functional outcomes and post-stroke anxiety (PSA) status

                                                          At 2 weeks    At 1 year                                                                             
  ------------------------------------------------------- ------------- ------------- -------- ------- ------- ------------- ------------- -------- --------- ---------
  National Institutes of Health Stroke Scale, mean (SD)   2.1 (2.2)     2.6 (3.2)     -0.835   0.411   0.253   1.0 (1.6)     2.3 (2.5)     -3.816   \<0.001   \<0.001
  Barthel Index, mean (SD)                                86.0 (18.7)   81.3 (20.9)   1.136    0.265   0.201   94.3 (12.3)   78.5 (23.8)   5.953    \<0.001   \<0.001
  Mini-Mental State Examination, mean(SD)                 24.7 (4.1)    22.8 (4.7)    2.242    0.025   0.093   25.7 (4.2)    22.0 (5.3)    4.062    \<0.001   \<0.001

p-values using t-tests,

p-values using logistic regression analysis adjusted for sex, previous depression, Hamilton depression Rating scale at 2 weeks.

PSA: Post-Stroke Anxiety
